Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ADC TherapeuticsADCT -6.67%41 Days Inventory is 113.08 as of Mar. 2026, which is 91% below its 10-year median of 1,282.37. GuruFocus rates ADCT with a GF Score™ of 41/100 and a GF Value™ of $2.09 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 921 Drug Manufacturers companies, ADC Therapeutics ranks worse than 96.42% on this metric.
The historical rank and industry rank for ADC Therapeutics's Days Inventory or its related term are showing as below:
ADCT'
s Days Inventory Range Over the Past 10 Years
Min: 202.55 Med: 1282.37 Max: 2914.24
Current: 617.72
During the past 10 years, ADC Therapeutics's highest Days Inventory was 2914.24. The lowest was 202.55. And the median was 1282.37.
ADCT's Days Inventory is ranked worse than 96.42% of 921
companies
in the Drug Manufacturers industry
Industry Median: 164.48
vs ADCT: 617.72
ADC Therapeutics's Days Inventory
declined
from Mar. 2025 (436.06) to Mar. 2026 (113.08).
Inventory Turnover measures how fast the company turns over its inventory within a year.
ADC Therapeutics's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.81.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
ADC Therapeutics's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.21.
ADC Therapeutics (NYSE:ADCT) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
ADC Therapeutics's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
ADC Therapeutics's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
ADC Therapeutics Days Inventory Related Terms
ADC Therapeutics Days Inventory Historical Data
* Premium members only.
The historical data trend for ADC Therapeutics's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ADCT vs GNLX, VXRT, COYA: Days Inventory Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, ADC Therapeutics's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ADC Therapeutics Days Inventory vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ADC Therapeutics's Days Inventory distribution charts can be found below:
* The bar in red indicates where ADC Therapeutics's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ADC Therapeutics (ADCT) has a Days Inventory of 113.08 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on ADC Therapeutics and its competitors. This is 91% below median its historical median of 1,282.37. Over the past decade, ADC Therapeutics' Days Inventory has ranged from 202.55 to 2,914.24. According to the industry distribution chart, ADC Therapeutics ranks #888 out of 921 companies in the Drug Manufacturers industry, placing it in the top 96.4%.
Is ADC Therapeutics' Days Inventory too high?
ADC Therapeutics' current Days Inventory of 113.08 is 91% below median its 10-year median of 1,282.37. Over the past 10 years, this metric has ranged from a low of 202.55 to a high of 2,914.24. The Drug Manufacturers industry median Days Inventory is 164.48. ADC Therapeutics' value of 113.08 is 31.3% below this industry median. Based on the distribution chart, ADC Therapeutics ranks #888 out of 921 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, ADC Therapeutics has a GF Score™ of 41/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ADC Therapeutics' Days Inventory compare to GNLX and VXRT?
According to the Drug Manufacturers industry distribution chart, ADC Therapeutics ranks #888 out of 921 companies for Days Inventory. This places ADC Therapeutics in the lower half of its industry. The industry median Days Inventory is 164.48. ADC Therapeutics' value of 113.08 is 31.3% below this benchmark. Historically, ADC Therapeutics' own Days Inventory has ranged from 202.55 to 2,914.24 over the past decade. While the company's 10-year median is 1,282.37 vs. the industry median of 164.48, ADC Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Drug Manufacturers company?
The median Days Inventory among Drug Manufacturers companies is 164.48, based on 921 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ADC Therapeutics's current Days Inventory of 113.08 is 31.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on ADC Therapeutics and its competitors. For the Drug Manufacturers industry, the median Days Inventory is 164.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ADC Therapeutics's current Days Inventory is 113.08, which is 91% below median its own 10-year median of 1,282.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ADC Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, ADC Therapeutics (ADCT) is currently considered Possible Value Trap. The stock's GF Value™ is $2.09, compared to a current price of $1.26 — trading 39.7% below its estimated fair value. The current Days Inventory is 113.08, which is 91% below median its 10-year median of 1,282.37 and 31.3% below the Drug Manufacturers industry median of 164.48. ADC Therapeutics' overall GF Score™ is 41/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For ADC Therapeutics (ADCT), the current Days Inventory is 113.08 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ADC Therapeutics (ADCT) Overvalued in 2026?
Based on GuruFocus' analysis, ADC Therapeutics stock appears to be undervalued.
The current stock price of $1.26 is trading 39.7% below its estimated GF Value™ of $2.09.
GuruFocus considers ADC Therapeutics to be Possible Value Trap.
Key valuation signals for ADCT:
Days Inventory: 113.08 (91% below median its 10-year median of 1,282.37)
GF Value™: $2.09 vs. price of $1.26 (39.7% below fair value)
Industry Position: 31.3% below the Drug Manufacturers median (#888 of 921)
No single metric tells the full story. See the ADCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
41GF Score
Get the complete analysis for ADCT
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ADCT has been successfully added to your 
